NASDAQ
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
♥ 571 Thanks from members
Jazz Pharmaceuticals (JAZZ) exhibits strong bullish sentiment, driven by record Q2 2026 total revenues of $1.2 billion, 16% YoY growth, raised full-year guidance, and robust performance in core franchises like Xywav and Epidiolex, alongside oncology momentum.